Kubo H.,Tohoku University |
Suzuki T.,Tohoku University |
Matsushima T.,Sysmex Corporation |
Ishihara H.,Sysmex Corporation |
And 6 more authors.
BMC Cancer | Year: 2014
Background: Lung cancer is one of the leading causes of cancer death worldwide. Even with complete resection, the prognosis of early-stage non-small cell lung cancer is poor due to local and distant recurrence, and it remains unclear which biomarkers are clinically useful for predicting recurrence or for determining the efficacy of chemotherapy. Recently, several lines of evidence have indicated that the enzymatic activity of cyclin-dependent kinases could be a clinically relevant prognostic marker for some cancers. We investigated whether the specific activity of cyclin-dependent kinases 1 and 2 could predict recurrence or death in early non-small cell lung cancer patients.Methods: Patients with newly diagnosed, pathologically confirmed non-small cell lung cancer were entered into this blinded cohort study. The activity of cyclin-dependent kinases was determined in 171 samples by the C2P® assay, and the results were subjected to statistical analysis with recurrence or death as a clinical outcome.Results: The Cox proportional hazards model revealed that the activity of cyclin-dependent kinase 1, but not 2, was a predictor of recurrence, independent of sex, age, and stage. By contrast, cyclin-dependent kinase 2 activity was a predictor of death, independent of sex and stage.Conclusion: This study suggested the possible clinical use of cyclin-dependent kinase 1 as a predictor of recurrence and cyclin-dependent kinase 2 as a predictor of overall survival in early-stage non-small cell lung cancer. Thus, a combination of activity of cyclin-dependent kinases 1 and 2 is useful in decision-making regarding treatment strategies for non-small cell lung cancer after surgery. © 2014 Kubo et al.; licensee BioMed Central Ltd.
Ihara H.,Toho University |
Watanabe T.,University of Hyogo |
Hashizume N.,Wayo Womens University |
Totani M.,Showa Womens University |
And 17 more authors.
Annals of Clinical Biochemistry | Year: 2010
Background: The aim of the present study was to evaluate standard reference material (SRM) 1955 commutability as a reference material for serum folate using automated methods. We also designed so as to reduce the intermethod variability present in different automated methods. Methods: Using a microbiological assay related to the 'information value' of SRM 1955 as a comparison method, we investigated the possibility of standardization for the assay values of serum folate as measured by the automated methods (Access, Centaur and Elecsys). In the assay of 50 patient sera by these automated methods, we corrected observed values by the SRM 1955 and compared with comparison values. Results: The observed values of SRM 1955 Levels I, II and III were within or outside (but near) a 95% prediction interval obtained from patient sera by the automated methods. The normalized residuals obtained from SRM 1955 were within ± 3.0 (in SD units), which enabled us to conclude that the SRM 1955 had a physicochemical characterization similar to native serum. Twelve patients were assessed as hypofolataemia (<6.0 ng/mL) and 38 patients as normal (≥6.0 ng/mL). Before correction, folate levels in six of 12 patients were lower than 6.0 ng/mL, and those in seven of 38 patients were higher than 6.0 ng/mL with the automated methods. After correction, low levels were found in four of 12 patients, and normal levels were found in 33 of 38 patients. Conclusions: The use of SRM 1955 would help to reduce the intermethod variability present in different automated methods for serum folate measurement.
Takeuchi M.,Nittobo Medical Co. |
Takeuchi M.,Osaka Prefecture University |
Kondo K.,Osaka Prefecture University |
Kuri H.,Osaka Prefecture University |
And 3 more authors.
Journal of the Electrochemical Society | Year: 2012
Cu via-filling is an essential technology for fabricating signal lines both on chips and on printed circuit boards and also through a silicon via in 3D wafer lever packaging for electrical devices. Generally, four additives, such as suppressors, accelerators, levelers and chloride ions, are added to a Cu electrodeposition bath in order to achieve bottom-up filling. The selection of additives and control of the additive concentrations are complex and cause increased cost and complicated quality control. In order to solve these problems, we succeeded in developing a bottom-up filling technique using only one additive, which has four types of functions. This additive is a diallylmethylamine copolymer, and contains cationic nitrogen, chloride ion and sulfur dioxide in its structure. The counter ion of the diallylmethylamine copolymer was the chloride ion or bromide ion. They were synthesized from the monomer with anions in an aqueous solution by radical polymerization. The surface morphology and cross sections of the electrodeposits were observed by scanning electron microscopy (SEM) and optical microscopy (OM). Linear sweep voltammetry (LSV) and quartz crystal microbalance (QCM) analyses were conducted. © 2012 The Electrochemical Society.
Chiba University, Nittobo Medical Co. and Nitto Boseki Co. | Date: 2011-06-13
The detection of a non-alcoholic steatohepatitis patient and the accurate discrimination between a normal person and a non-alcoholic steatohepatitis patient can be achieved by measuring alanine-glyoxylate amino transferase in a sample.
Noda K.,Nittobo Medical Co. |
Noda K.,Chiba University |
Sogawa K.,Chiba University |
Kikuchi W.,Nittobo Medical Co. |
And 10 more authors.
Proteomics - Clinical Applications | Year: 2011
Purpose: We previously identified novel biomarker candidates in heavy consumers of alcohol using serum proteome analysis. Among several candidates, a 5.9kDa peptide identified as a fragment of the fibrinogen alpha C chain (FIC5.9) was the most promising. To move FIC5.9 toward potential diagnostic use, we developed an enzyme immunoassay that enables measurement of serum FIC5.9 levels. Experimental design: Two monoclonal antibodies specific to the N and C-termini of the 5.9-kDa peptide were used to develop a FIC5.9 sandwich ELISA. The assay was evaluated by comparing the results with those obtained by the stable isotope-labeled dilution mass spectrometry (SID-MS) using the ClinProt™ system. Results: The ELISA results correlated with the SID-MS findings (slope=0.795, intercept=-0.011, r2=0.908) and the performance of the ELISA was satisfactory in terms of recovery (98.5-103.0%) and within-run (1.4-4.7%) and between-day (2.8-8.4%) reproducibility. The assay was capable of detecting changes in FIC5.9 during abstinence from drinking in patients with alcohol dependency (p<0.0001). Conclusions and clinical relevance: The sandwich ELISA developed in this study will be useful for validation of the diagnostic significance of serum FIC5.9 levels in various pathological conditions, including alcoholism. © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.